Sintilimab immunotherapy is not only effective when combined with gemcitabine and chemotherapy, but it may be a novel option when added to paclitaxel/nab-paclitaxel in squamous non–small cell lung cancer.
First Look
Triple Therapy for Squamous NSCLC Shows Real-World Clinical Benefit
